United States · FDA National Drug Code directory
ZYNYZ
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 50881-006_91ad9008-46bd-4619-946f-75174fceaf56
- Product NDC
- 50881-006
- Form
- INJECTION
- Composition / generic term
- retifanlimab-dlwr
- Labeler
- Incyte Corporation
- Marketing category
- BLA
- Marketing start / end (source format)
- 20230322
- Source listing expiry
- 20271231
Source-listed ingredients
- RETIFANLIMAB — 25 mg/mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 VIAL, SINGLE-USE in 1 CARTON (50881-006-03) / 20 mL in 1 VIAL, SINGLE-USE · 50881-006-03
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →